Clinical trialNCT03817320Active, not recruitingPhase 1/PHASE2Interventional

PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

SponsorTherapeutic Advances in Childhood Leukemia ConsortiumEnrollment24ALL, ChildhoodLymphoblastic Leukemia, Acute, ChildhoodLymphoblastic Lymphoma, Childhood

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a phase 1/2 study of a drug called Ixazomib in combination with cytotoxic chemotherapy consisting of Vincristine, Dexamethasone, Asparaginase, and Doxorubicin (VXLD).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Terzah Horton, MD
Baylor College of Medicine
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

18 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia

the Children'S Hospital at Westmead
Westmead, New South Wales, Australia

United States

Children'S Hospital Los Angeles
Los Angeles, California, United States
Children'S Hospital Orange County
Orange, California, United States
Children'S National Medical Center
Washington D.C., District of Columbia, United States
University of Miami
Miami, Florida, United States
Children'S Healthcare of Atlanta
Atlanta, Georgia, United States
C.S. Mott Children'S Hospital
Ann Arbor, Michigan, United States
Children'S Hospital and Clinics of Minnesota
Minneapolis, Minnesota, United States
Columbia University Medical Center
New York, New York, United States
Levine Cancer Institute
Charlotte, North Carolina, United States
University Hospitals Seidman Cancer Center
Cleveland, Ohio, United States
Nationwide Children'S Hospital
Columbus, Ohio, United States
Doernbecher Children'S Hospital
Portland, Oregon, United States
Children'S Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
St. Jude Children'S Research Hospital
Memphis, Tennessee, United States
University of Texas, Southwestern
Dallas, Texas, United States
Cook Children'S Medical Center
Fort Worth, Texas, United States
Texas Children'S Hospital/baylor University
Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Asparaginase →Dexamethasone →Doxorubicin →Ixazomib →Leucovorin →Methotrexate →Triple ITVincristine →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 12 Feb 2019
Primary completion: 3 Dec 2023
Completion: 30 Jun 2025
Last update posted: 17 Jun 2025
Registered enrollment: 24
Registry id: NCT03817320

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.